The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Antifungal therapy with an emphasis on biofilms
Open accessAbstract
Fungal infections are on the rise as advances in modern medicine prolong the lives of severely ill patients. Fungi are eukaryotic organisms and there are a limited number of targets for antifungal drug development; as a result the antifungal arsenal is exceedingly limited. Azoles, polyenes and echinocandins constitute the mainstay of antifungal therapy for patients with life-threatening mycoses. One of the main factors complicating antifungal therapy is the formation of fungal biofilms, microbial communities displaying resistance to most antifungal agents. A better understanding of fungal biofilms provides for new opportunities for the development of urgently needed novel antifungal agents and strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“sessile cells show high levels of tolerance to antifungal therapy as compared to their planktonic counterparts [21,22].”
From Antifungal therapy of Candida biofilms: Past, present and future (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“Unfortunately, the mortality rates associated with these mycoses remain unacceptably high, very often higher than 50% [1,2], which clearly indicates major shortcomings and limitations in the clinical management of patients with fungal infections.”
Biofilms: Microbial Life on Surfaces
Donlan, R. M. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0809.020063 · Cited by 4,145
Bacterial Biofilms in Nature and Disease
Costerton, J. W., Cheng, K. J., Geesey, G. G., Ladd, T. I., Nickel, J. C., Dasgupta, M., & Marrie, T. J. (1987) · Annual Review of Microbiology · doi:10.1146/annurev.mi.41.100187.002251 · Cited by 3,145
Chandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Biofilm Formation: A Clinically Relevant Microbiological Process
Donlan, R. M. (2001) · Clinical Infectious Diseases · doi:10.1086/322972 · Cited by 1,343
Antifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202
Sardi, J. C. O., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., & Mendes Giannini, M. J. S. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.045054-0 · Cited by 1,184
Candida Infections of Medical Devices
Kojic, E. M., & Darouiche, R. O. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.2.255-267.2004 · Cited by 1,055
Cited by
Sorted by citations
Effect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study
Lara, H. H., Romero-Urbina, D. G., Pierce, C., Lopez-Ribot, J. L., Arellano-Jiménez, M. J., & Jose-Yacaman, M. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0147-8 · Cited by 323
“This is important as both filamentation and development of biofilms represent two of the main virulence factors of Candida species [11].”
BackgroundInfluentialSelf-citationCandida albicans biofilm growth and dispersal: contributions to pathogenesis
Wall, G., Montelongo-Jauregui, D., Vidal Bonifacio, B., Lopez-Ribot, J. L., & Uppuluri, P. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.04.001 · Cited by 263
“albicans cells within a biofilm display high-levels of resistance to azoles and polyenes[33,34], with biofilms formed under flow conditions exhibiting even higher resistance [18].”
BackgroundSelf-citationFreires, I. A., Murata, R. M., Furletti, V. F., Sartoratto, A., de Alencar, S. M., Figueira, G. M., Rodrigues, J. A. D. O., Duarte, M. C. T., & Rosalen, P. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099086 · Cited by 201
“This same mechanism accounts for the antifungal activity of polyenes such as nystatin and amphotericin B [42].”
BackgroundCurrent Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy
Wall, G., & Lopez-Ribot, J. L. (2020) · Antibiotics · doi:10.3390/antibiotics9080445 · Cited by 183
“As a consequence, and in stark contrast with antibacterials, the current antifungal armamentarium is still very limited [8,9].”
ResultTargeting Candida albicans filamentation for antifungal drug development
Vila, T., Romo, J. A., Pierce, C. G., McHardy, S. F., Saville, S. P., & Lopez-Ribot, J. L. (2017) · Virulence · doi:10.1080/21505594.2016.1197444 · Cited by 174
“major classes of antifungal drugs: polyenes, azoles and echinocandins.(14,15) However, this arsenal is compromised by problems of selectivity, toxicity, and the development of resistance.”
BackgroundSelf-citation
Metadata
- Authors
- Pierce, C. G., Srinivasan, A., Uppuluri, P., Ramasubramanian, A. K., & López-Ribot, J. L.
- Affiliations
- The University of Texas at San Antonio (US)
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 13
- Issue
- 5
- Pages
- 726-730
- ISSN
- 1471-4892 (ISSN-L)
- PMC
- PMC3795934
- OpenAlex
- W2076025899
- Cited by
- 173
- References
- 64
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 7 · 2023: 12 · 2022: 16 · 2021: 7 · 2020: 19 · 2019: 18 · 2018: 14 · 2017: 11 · 2016: 15 · 2015: 13 · 2014: 9 · 2013: 1
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Current Opinion in Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Dental and Craniofacial Research (R01DE023510)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- antifungal therapy, fungal biofilms, antifungal resistance, azoles, polyenes, echinocandins, fungal infection, antifungal drug development
- MeSH terms
- Animals, Antifungal Agents, Fungi, Humans, Mycoses, Biofilms, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
